Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity
A 2022 analysis published in Diabetes, Obesity and Metabolism found that semaglutide treatment was associated with significant improvements in patient-reported energy levels and physical functioning scores, with improvements correlating with both weight loss magnitude and reductions in inflammatory markers (Wilding et al., Diabetes, Obesity and Metabolism, 2022, What GLP-1 Medications Cannot Do for Fatigue This is worth addressing directly, because theres a real risk of patients attributing all their fatigue to weight and expecting GLP-1 medications to fix everything
Stable Weekly Serum Absorption: Delivers a predictable, slow release therapeutic payload when administered once weekly on a consistent schedule
individual clinical judgment should always guide specific prescribing decisions
However, your body is primarily adjusting to the baseline dose, so immediate weight loss on the scale is rare